Abstracts tagged "Biologicals"

Abstract Number: 0366 • ACR Convergence 2020
Symptoms of Peripheral Arthritis Are Significantly Improved in Patients with Ankylosing Spondylitis Treated with Secukinumab
Philip Mease¹, Atul Deodhar², Renato Calheiros³, Xiangyi Meng⁴, Todd Fox⁵ and Xenofon Baraliakos⁶, ¹Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Novartis Pharmaceuticals Corporation, Hoboken, NJ, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵Novartis Pharma AG, Aesch, Switzerland, ⁶Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany
Background/Purpose: Ankylosing spondylitis (AS) is a chronic inflammatory disease of the axial skeleton associated with pain, stiffness, and disability.1 Up to 66% of patients (pts)…
Abstract Number: 0584 • ACR Convergence 2020
Total Cost of Care for Patients with Rheumatoid Arthritis
Kjel Johnson¹, Rebecca Karos², Elisea Avalos-Reyes³, Fabio Casadio⁴, Michele Hamburger⁵ and Chiara Leprai⁴, ¹CVS Health, Lincoln, RI, ²CVS Health, Wellesley, MA, ³CVS Health, Irving, TX, ⁴CVS Health, New York, NY, ⁵Frances Hamburger Institute, Hauppauge, NY
Background/Purpose: The range of medical costs associated with rheumatoid arthritis (RA) is, in part, related to the various treatment options. Treatment for RA focuses on…
Abstract Number: 0806 • ACR Convergence 2020
Identification and Adjustment for Factors Associated with Clinical Response in Rheumatoid Arthritis Clinical Trials to Improve Comparisons of Treatment Efficacy
Anthony Cordisco¹ and Joshua Baker¹, ¹Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA
Background/Purpose: Numerous clinical trials have been published in rheumatoid arthritis (RA), but comparing efficacies of disease-modifying anti-rheumatic drugs (DMARDs) is complicated by a lack of…
Abstract Number: 0881 • ACR Convergence 2020
Reduction of Anterior Uveitis Flares in Patients with Axial Spondyloarthritis During Certolizumab Pegol Treatment: 96-Week Results from the C-VIEW Study
Irene van der Horst-Bruinsma¹, Rianne van Bentum¹, Frank Verbraak², Thomas Rath³, James Rosenbaum⁴, Bengt Hoepken⁵, Oscar Irvin-Sellers⁶, Thomas Kumke⁵, Lars Bauer⁵ and Martin Rudwaleit⁷, ¹Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ²Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, ³St Franziskus-Hospital, Münster, Germany, ⁴Oregon Health & Science University, Portland, OR, ⁵UCB Pharma, Monheim am Rhein, Germany, ⁶UCB Pharma, Slough, United Kingdom, ⁷Department of Internal Medicine and Rheumatology, Klinikum Bielefeld, Germany
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular manifestation in axial spondyloarthritis (axSpA), affecting up to 40% of patients and causing significant burden.1…
Abstract Number: 1038 • ACR Convergence 2020
STAT1 and JAK2 Are the Most Appropriate Targets of JAK-inhibitor Therapy for Sarcoidosis: An In-silico Meta-nalysis
Marcia Friedman¹, Brian Le², Dongseok Choi² and James Rosenbaum², ¹Oregon Health and Science University, Portland, OR, ²Oregon Health & Science University, Portland, OR
Background/Purpose: Our group was the first to contend that STAT1 mediated genes were expressed in sarcoidosis. Since that time, several other groups have found similar…
Abstract Number: 1349 • ACR Convergence 2020
Guselkumab Provides Domain-Specific and Comprehensive Efficacy as Assessed Using Composite Endpoints in Patients with Active Psoriatic Arthritis
Laura Coates¹, Christopher Ritchlin², Laure Gossec³, Philip Helliwell⁴, Proton Rahman⁵, Elizabeth Hsia⁶, Alexa Kollmeier⁷, Xie Xu⁸, Chetan Karyekar⁹, May Shawi¹⁰, Wim Noël¹¹, Yusang Jiang¹², Shihong Sheng¹², Prasheen Agarwal¹² and Philip Mease¹³, ¹University of Oxford, Oxford, United Kingdom, ²Department of Medicine, University of Rochester Medical Center, Rochester, NY, ³Sorbonne Université and Hôpital Universitaire Pitié Salpêtrière, Paris, France, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Memorial University of Newfoundland, Department of Medicine, St John's, Canada, ⁶Janssen Research & Development, LLC and University of Pennsylvania Medical Center, Spring House, PA, ⁷Janssen Research & Development, LLC, La Jolla, CA, ⁸Janssen Research & Development, LLC, San Marcos, CA, ⁹Janssen Global Services, LLC, Horsham, PA, ¹⁰Janssen Global Services, LLC, Toronto, ON, Canada, ¹¹Janssen Medical Affairs, LLC, Beerse, Belgium, ¹²Janssen Research & Development, LLC, Spring House, PA, ¹³Seattle Rheumatology Associates, P.L.L.C., Seattle, WA
Background/Purpose: Guselkumab (GUS) is a human monoclonal antibody that specifically binds to the p19-subunit of IL-23. GUS has demonstrated efficacy across the various manifestations of…
Abstract Number: 1485 • ACR Convergence 2020
LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis
Celeste Scotti¹, Joseph Gimbel², Didier Laurent¹, Aviv Madar³, Thomas Peters¹, Yunyu Zhang³, Florine Polus¹, Michael Beste³, Igor Vostiar¹, Subhajit Choudhury⁴, Nicole Gerwin¹, Jörg Goldhahn⁵, Matthias Schieker¹ and Ronenn Roubenoff¹, ¹Novartis Institutes for BioMedical Research, Basel, Switzerland, ²Arizona Research Center, Phoenix, ³Novartis Institutes for BioMedical Research, Cambridge, ⁴Biostatistics & Pharmacometrics, Novartis Healthcare Pvt. Ltd., Hyderabad, India, ⁵Department of Health Sciences and Technology, ETH Zürich, Zurich, Switzerland
Background/Purpose:LNA043 is a modified human angiopoietin-like 3 (ANGPTL3) protein identified in a phenotypic screen for inducers of chondrogenesis and cartilage repair. The primary objective of…
Abstract Number: 1924 • ACR Convergence 2020
Low Immunogenicity in Patients with Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from the Randomized Controlled Portion and the Open-Label Follow-Up of a Phase 3 Trial
John H. Stone¹, Navita L. Mallalieu² and Min Bao³, ¹Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ²Roche Innovation Center, New York, NY, ³Genentech, South San Francisco, CA
Background/Purpose: Tocilizumab (TCZ) has low immunogenicity in patients with rheumatoid arthritis (RA).1 The risk for TCZ immunogenicity remains to be determined in patients with giant…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].